2024
Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances
Havlik J, Rhee T, Rosenheck R. Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances. PLOS ONE 2024, 19: e0302544. PMID: 38683850, PMCID: PMC11057773, DOI: 10.1371/journal.pone.0302544.Peer-Reviewed Original ResearchConceptsIllicit substance use disordersCannabis use disorderSubstance use disordersMental health-related quality of lifeUse disorderTreatment usePast-year CUDRates of treatment usePast-year substance use disorderMental health-related qualityMental health related qualityBehavioral health factorsLegal statusNegative associationNESARC-IIISUD treatment useMultiple regression analysisDisordersHealth-related quality of lifeIllegal substancesHealth related qualityUnadjusted analysisQuality of lifeAUDDiagnostic factors
2023
Victimization in schizophrenia and its relation to violence
Buchanan A, Stefanovics E, Rosenheck R. Victimization in schizophrenia and its relation to violence. Schizophrenia Research 2023, 255: 52-58. PMID: 36963231, DOI: 10.1016/j.schres.2023.03.018.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialMental health symptomsStudy entryCross-sectional designAntipsychotic treatmentEffectiveness trialSchizophrenia symptomsMultivariate analysisHealth symptomsSchizophreniaViolent behaviorSubstance useSymptomsRecent victimizationPotential causesAggressive behaviorChildhood experiencesBaselineMore incidentsCorrelatesTreatmentVictims of violenceSexual abuseClose friendsMost perpetratorsIncreasing Use of Cannabis for Medical Purposes Among U.S. Residents, 2013–2020
Rhee T, Rosenheck R. Increasing Use of Cannabis for Medical Purposes Among U.S. Residents, 2013–2020. American Journal Of Preventive Medicine 2023, 65: 528-533. PMID: 36918131, PMCID: PMC10440227, DOI: 10.1016/j.amepre.2023.03.005.Peer-Reviewed Original ResearchConceptsMedical cannabis useAverage annual percentage changeAnnual percentage changeUse of cannabisCannabis useClinical subgroupsPercentage changeMultivariable-adjusted modelsCorrelates of cannabisSimilar significant increaseMedical cannabisDrug useDistrict of ColumbiaCannabisMedical purposesNationwide increaseSignificant increaseNational surveyDichotomous questionsU.S. residentsSubgroupsTemporal trendsAssociation of Recent and Past Suicide Attempts With Health-Related Quality of Life.
Bommersbach T, Rosenheck R, Rhee T. Association of Recent and Past Suicide Attempts With Health-Related Quality of Life. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36856537, DOI: 10.4088/jcp.22m14441.Peer-Reviewed Original ResearchConceptsMental component scorePhysical component scoreSuicide prevention initiativesSuicide attemptsOverall health-related qualityMajor public health priorityPrevention initiativesHealth-related qualitySubstance use comorbiditiesMeasures of HRQOLRelated Conditions Wave IIILower MCS scoresMultivariable regression analysisPublic health prioritySubstance use disordersComponent scoresNational Epidemiologic SurveyQuality of lifeRecent suicide attemptAssociation of suicidePast suicide attemptsPrior attemptsMCS scoresUnadjusted analysesHealth priorityMultimorbidity and Correlates of Comorbid Depression and Generalized Anxiety Disorder in a Nationally Representative US Sample
Jegede O, Stefanovics E, Rhee T, Rosenheck R. Multimorbidity and Correlates of Comorbid Depression and Generalized Anxiety Disorder in a Nationally Representative US Sample. The Journal Of Nervous And Mental Disease 2023, 211: 355-361. PMID: 36807207, DOI: 10.1097/nmd.0000000000001625.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAdditional psychiatric diagnosesRepresentative US sampleComorbid groupPsychiatric disordersPsychiatric diagnosisPoor mental health qualityMental health-related qualityPoorer mental health-related qualityAnxiety disordersHealth-related qualityAdditional psychiatric disordersNationally Representative US SampleMental health qualityLogistic regression analysisSubstance use disordersNational Epidemiologic SurveyMDD-only groupRelated Conditions-IIISingle disorder groupsGeneralized anxiety disorderSingle diagnosis groupsPsychiatric comorbidityComorbid depressionDepressive disorderMental health problems of black and white children in a nationally representative epidemiologic survey
Bommersbach T, Rhee T, Jegede O, Rosenheck R. Mental health problems of black and white children in a nationally representative epidemiologic survey. Psychiatry Research 2023, 321: 115106. PMID: 36791593, DOI: 10.1016/j.psychres.2023.115106.Peer-Reviewed Original ResearchConceptsMental health problemsHealth problemsWhite childrenAdverse mental health problemsBlack childrenMental health servicesNon-Hispanic blacksDepression/anxietyMental health conditionsInternalizing conditionsPotential confoundersRoutine screeningChild healthConduct problemsEpidemiologic SurveyHealth servicesMultivariate analysisSocio-economic disadvantageHealth conditionsRacial differencesChildrenNational surveySuicide ratesChildhood experiencesGreater exposureCan multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration
Rosenheck R, Anand S, Kurtz S, Hau C, Smedberg D, Pontzer J, Ferguson R, Davis C. Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration. Trials 2023, 24: 85. PMID: 36747254, PMCID: PMC9900548, DOI: 10.1186/s13063-023-07094-6.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsLAI risperidoneClinical practiceLAI second-generation antipsychoticsInjectable second-generation antipsychoticsPractical clinical trialsVeterans Health AdministrationClinical trial resultsStudy publicationDiagnosis of schizophreniaNational administrative dataLongitudinal observational analysisLAI paliperidoneOral antipsychoticsReal-world practiceInjectable risperidoneTrial findingsClinical trialsLAI treatmentRisperidoneSchizoaffective disorderHealth AdministrationCooperative StudyAntipsychoticsDrug expendituresImpact of multi-site clinical trial results on clinical practice: Use of risperidone to treat PTSD nationally in the veterans health administration
Rosenheck R, Kurtz S, Anand S, Hau C, Smedberg D, Sicilia R, Pontzer J, Ferguson R. Impact of multi-site clinical trial results on clinical practice: Use of risperidone to treat PTSD nationally in the veterans health administration. Psychiatry Research 2023, 321: 115071. PMID: 36720177, DOI: 10.1016/j.psychres.2023.115071.Peer-Reviewed Original ResearchConceptsClinical practiceNational VHA administrative dataOral second-generation antipsychoticsUse of risperidoneVHA administrative dataSecond-generation antipsychoticsMulti-site clinical trialVeterans Health AdministrationClinical trialsEffectiveness trialHealth AdministrationRisperidoneCooperative StudyYear of publicationAdministrative dataPTSDTrialsYearsAntipsychoticsStudy resultsAdministrationGender differences in outcomes of early intervention services for first episode psychosis
Hong S, Bennett D, Rosenheck R. Gender differences in outcomes of early intervention services for first episode psychosis. Early Intervention In Psychiatry 2023, 17: 715-723. PMID: 36623822, PMCID: PMC10329725, DOI: 10.1111/eip.13367.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisEarly intervention servicesClinical trialsEpisode psychosisInitial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) studyEarly interventionIntervention servicesRandomized clinical trialsComorbid substance useUS clinical trialsSignificant gender differencesNegative Syndrome ScaleBaseline gender differencesGender differencesSchizophrenia spectrum disordersAntipsychotic exposureUsual careBaseline characteristicsMood symptomsDepression subscalePsychotic disordersMasked evaluatorsSchizoaffective disorderSyndrome ScaleSecondary analysis
2022
Beyond Supported Housing: Correlates of Improvements in Quality of Life Among Homeless Adults with Mental Illness
O’Connell M, Tsai J, Rosenheck R. Beyond Supported Housing: Correlates of Improvements in Quality of Life Among Homeless Adults with Mental Illness. Psychiatric Quarterly 2022, 94: 49-59. PMID: 36538200, DOI: 10.1007/s11126-022-10010-x.Peer-Reviewed Original ResearchEmpirical Considerations of an Unsolved Conundrum: Disability Payments and Work
Rosenheck R. Empirical Considerations of an Unsolved Conundrum: Disability Payments and Work. Schizophrenia Bulletin 2022, 49: 7-8. PMID: 36153762, PMCID: PMC9809999, DOI: 10.1093/schbul/sbac136.Peer-Reviewed Original ResearchHumansInsurance, DisabilityRacial and ethnic differences in suicidal behavior and mental health service use among US adults, 2009–2020
Bommersbach T, Rosenheck R, Rhee T. Racial and ethnic differences in suicidal behavior and mental health service use among US adults, 2009–2020. Psychological Medicine 2022, 53: 5592-5602. PMID: 36106374, PMCID: PMC10482716, DOI: 10.1017/s003329172200280x.Peer-Reviewed Original ResearchConceptsPast-year suicidal ideationMental health service useHealth service useService useSuicidal ideationSuicide attemptsRace/ethnicityHispanic individualsWhite individualsEthnic differencesSuicidal behaviorSuicidal thoughts/behaviorsMental health servicesThoughts/behaviorsSI/SAMultivariable adjustmentUS adultsUS civilianDrug useHealth servicesProportion of whitesPast-year suicide attemptsHealthcare systemNational surveySuicide rates
2013
Incarceration Histories of Homeless Veterans and Progression Through a National Supported Housing Program
Tejani N, Rosenheck R, Tsai J, Kasprow W, McGuire J. Incarceration Histories of Homeless Veterans and Progression Through a National Supported Housing Program. Community Mental Health Journal 2013, 50: 514-519. PMID: 23728839, DOI: 10.1007/s10597-013-9611-9.Peer-Reviewed Original ResearchSecond generation antipsychotics: evolution of scientific knowledge or uncovering fraud
Rosenheck R. Second generation antipsychotics: evolution of scientific knowledge or uncovering fraud. Epidemiology And Psychiatric Sciences 2013, 22: 235-237. PMID: 23388147, PMCID: PMC8367331, DOI: 10.1017/s2045796012000662.Peer-Reviewed Original Research
2012
Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study
Zhang X, Chen D, Xiu M, Haile C, He S, Luo X, Zuo L, Rosenheck R, Kosten T, Kosten T. Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study. Psychological Medicine 2012, 43: 1651-1660. PMID: 23149169, DOI: 10.1017/s0033291712002590.Peer-Reviewed Original ResearchConceptsDrug-naive patientsFES patientsGeneral populationCognitive functionChronic schizophreniaHealthy controlsSmoking ratesFirst-episode drug-naive patientsFirst-episode schizophrenia patientsQuantity of smokingPositive symptom subscale scoresCase-control studyHigh smoking ratesSymptom subscale scoresCase-control designNegative Symptom ScaleTotal PANSSCigarette smokingFirst episodeNicotine dependenceFagerström TestPatientsPsychotic disordersSmokingSymptom Scale
2009
Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck RA, Sernyak MJ. Developing A Policy For Second-Generation Antipsychotic Drugs. Health Affairs 2009, 28: w782-w793. PMID: 19622538, DOI: 10.1377/hlthaff.28.5.w782.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsAntipsychotic drugsRisk/benefit profileSecond-generation antipsychotic drugsMetabolic side effectsTreatment of schizophreniaAdverse eventsBenefit profileLower riskOld drugsSide effectsPrior authorizationDrugsCheaper drugsGeneric drugsEducational preparationWidespread implementationGood acceptanceSuch proceduresAntipsychoticsPatientsTherapySchizophrenia
2007
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysisEvaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
Rosenheck R. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. The British Journal Of Psychiatry 2007, 191: 238-245. PMID: 17766765, DOI: 10.1192/bjp.bp.106.035063.Peer-Reviewed Original ResearchDr. Rosenheck and Colleagues Reply
ROSENHECK R, STROUP T, SWARTZ M, McEVOY J, DAVIS S, KEEFE R, HSIAO J, LIEBERMAN J. Dr. Rosenheck and Colleagues Reply. American Journal Of Psychiatry 2007, 164: 678-680. PMID: 17403984, DOI: 10.1176/ajp.2007.164.4.678a.Peer-Reviewed Original ResearchPractical applications of recent antipsychotic effectiveness data.
Lieberman J, Harvey P, Newcomer J, Rosenheck R. Practical applications of recent antipsychotic effectiveness data. The Journal Of Clinical Psychiatry 2007, 68: 151-62. PMID: 17284143, DOI: 10.4088/jcp.v68n0120.Peer-Reviewed Original Research